Anti-amyloid therapies signal potential for early Alzheimer’s disease
By GlobalData Healthcare
30 Jun 2021 (Last Updated June 30th, 2021 15:07)
On June 24, the FDA granted breakthrough therapy designation (BTD) to two pipeline drugs: Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab for the treatment of Alzheimer’s disease (AD).
Credit: Robert Kneschke / Shutterstock.
Share Article
On June 24, the FDA granted breakthrough therapy designation (BTD) to two pipeline drugs: Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab for the treatment of Alzheimer’s disease (AD). Currently, the AD market is dominated by symptom-based therapies with modest efficacy. Earlier this month, Biogen’s Aduhelm (aducanumab) received FDA approval, and thus it is the first and only approved AD disease-modifying treatment (DMT). GlobalData forecasts that Aduhelm will generate $5.5B globally by 2027. Lecanemab and donanemab could be the next monoclonal antibodies (mAbs) against amyloid to receive FDA approval.